Saturday, November 21, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Healthcare

BioNTech’s $650 Million R&D Quarter: Shareholders Back Board Expansion as Market Awaits Lung Cancer Data

Rodolfo Hanigan by Rodolfo Hanigan
May 17, 2026
in Healthcare, Pharma & Biotech, TecDAX
0
BioNTech Stock
0
SHARES
77
VIEWS
Share on FacebookShare on Twitter

Despite sitting on nearly $20 billion in cash, BioNTech is burning through money at an accelerating pace as it races to reposition itself for the post-Covid era. Research and development costs surged past $650 million in the first quarter alone, while vaccine revenue – the engine that once propelled the company – shrank to just $138 million. The result was a substantial net loss, underscoring the financial strain of a transition that hinges entirely on clinical success.

Shareholders have thrown their weight behind the strategy. At the annual general meeting on 15 May 2026, 92% of the share capital was represented, and investors approved every management proposal. The supervisory board will now expand from six to eight members, with Iris Löw-Friedrich and Susanne Schaffert – both seasoned oncology executives – joining the oversight body. An accompanying resolution authorised the creation of new capital worth up to 50% of the current share base, giving the board flexibility to fund the swelling pipeline.

The revenue picture underscores the depth of the pivot. BioNTech reported first-quarter revenues of just €118.1 million, down from €182.8 million a year earlier. The company is sticking to its full-year guidance of $2.3 billion to $2.6 billion in total revenue, while simultaneously running a share buyback programme of up to $1.0 billion. For now, the market remains unimpressed.

The stock closed at €76.95 on Friday, shedding 2.22% on the day. It has lost 8.01% over the past month and sits roughly 7% lower since the start of 2026. Technically, the shares are trading below their key moving averages, with the gap to the long-term average exceeding eleven percentage points – a sign that institutional conviction has yet to return.

Should investors sell immediately? Or is it worth buying BioNTech?

The next major catalyst is just weeks away. On 21 May, the embargo lifts for abstracts to be presented at the ASCO annual meeting in Chicago. BioNTech will release Phase 2 data from the ROSETTA-Lung-02 study on 29 May, testing its experimental bispecific antibody Pumitamig in combination with chemotherapy against the established standard of care, Merck’s Keytruda (pembrolizumab). Success in first-line non-small cell lung cancer would send a powerful signal to both the analyst community and a skeptical investor base.

That divergence is already baked into analyst price targets. Canaccord keeps a “Buy” rating with a $158 target, while Leerink is far more cautious at just $94. The spread reflects how heavily the stock’s valuation has become tethered to the outcome of these clinical readouts.

The Pumitamig data marks only the beginning. BioNTech has mapped out seven late-stage oncology data readouts for this year and expects to have fifteen Phase 3 clinical trials running by year-end. A convincing result from ROSETTA-Lung-02 would provide the clinical underpinning for a strategic overhaul that has so far been backed by shareholders but ignored by the market.

Ad

BioNTech Stock: Buy or Sell?! New BioNTech Analysis from November 21 delivers the answer:

The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 21.

BioNTech: Buy or sell? Read more here...

Tags: BioNTech
Rodolfo Hanigan

Rodolfo Hanigan

Related Posts

Novo Nordisk Stock
Analysis

Novo Nordisk Faces a New Front: 300-Fold Rise in GLP-1 Scripts for Children Under 12

September 7, 2026
Novo Nordisk Stock
European Markets

Novo Nordisk’s Two-Front Battle: US Price Concessions Meet a Pipeline Fighting for Credibility

September 6, 2026
Infineon Stock
AI & Quantum Computing

Infineon’s Grid-to-Core Gambit: New Alliance Deepens AI Data-Center Push as Analysts Flag Upside

September 6, 2026
Next Post
Sparc AI Stock

Sparc AI’s Dual Push into Ukraine and Tampa Puts Navigation Software to the Test

Uranium Energy Stock

Uranium Energy Eyes Two Key Catalysts Over the Next Two Months as Stock Tests Support

Ocugen Stock

Ocugen Names Interim CMO as $130M Convertible Fuels Gene Therapy Push Toward FDA Filings

Recommended

WM stock news

Spire Wealth Management Shows Confidence in Churchill Downs Incorporated with New Acquisition and Bet on Future Growth

3 years ago
Chevron Stock

Chevron Shares Surge Amid Global Oil Supply Disruption

8 months ago
Q2 Holdings Stock

Inclusion in S&P SmallCap 600 Index Ignites Q2 Holdings Stock Rally

1 year ago
REV Stock

REV Group Shares Hit Record High Amid Political Scrutiny

1 year ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum DroneShield Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Nvidia Posts a Record Quarter, but Rate-Hike Fears Still Set the Tone

Home Depot Beats, Shares Slip: Bigger Tickets, Fewer Customers

Rotation, Not Panic: Retailers Test Where Tech’s Money Went

At 5.15%, the 10-Year Treasury Picks the Winners

Bitcoin Slips Below $70,000, and a Samsung Rumor Lifts Modine

Huang Exits, Cisco Reports: Who Actually Gets Paid for AI

Trending

CrowdStrike Stock
Newsletter

93% of Stocks Fall as CrowdStrike Courts Zscaler

by Stephanie Dugan
November 21, 2026
0

Dear readers, The question heading into Friday was whether Anthropic would hold its $83 offer price. It...

Nvidia Stock

Anthropic Lists at a Premium, but the Sell-Off Keeps Going

November 20, 2026
Bitcoin Stock

Anthropic’s $81 Billion IPO Meets a Market in Need of Good News

November 19, 2026
Nvidia Stock

Nvidia Posts a Record Quarter, but Rate-Hike Fears Still Set the Tone

November 18, 2026
Home Depot Stock

Home Depot Beats, Shares Slip: Bigger Tickets, Fewer Customers

November 17, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • 93% of Stocks Fall as CrowdStrike Courts Zscaler
  • Anthropic Lists at a Premium, but the Sell-Off Keeps Going
  • Anthropic’s $81 Billion IPO Meets a Market in Need of Good News

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com